Faculty Opinions recommendation of Remdesivir in adults with severe COVID-19: a randomised

A Faculty Opinions recommendation for a clinical trial investigating the antiviral drug Remdesivir in adults with severe COVID-19. The trial was randomized, double-blind, and placebo-controlled, involving multiple centers. The dataset, sourced from paperswithcode, likely contains tabular results from this medical research study.

Use Cases

• Analyzing treatment efficacy metrics for antiviral drugs (inferred from domain, verify after download)
• Training models to predict clinical trial outcomes from structured results (inferred from domain, verify after download)
• Benchmarking drug performance against placebo controls in virology research (inferred from domain, verify after download)

Strengths

• Published on paperswithcode, a platform for machine learning research.
• Associated with a specific, peer-reviewed clinical trial design (randomized, double-blind, placebo-controlled, multicentre).

Limitations

• Metadata is minimal; actual content requires verification after download.
• Row count, column definitions, and sample data are unknown.
• License is listed as closed, which may restrict usage.

Provenance

Source

Gavin Koh, GlaxoSmithKline (United Kingdom)

Collection Method

Likely extracted or referenced from a published clinical trial.